PMID- 17457280
OWN - NLM
STAT- MEDLINE
DCOM- 20070618
LR  - 20191110
IS  - 0761-8417 (Print)
IS  - 0761-8417 (Linking)
VI  - 63
IP  - 1
DP  - 2007 Feb
TI  - [New biological treatments for lung cancer].
PG  - 20-8
AB  - Therapies targeted on cell signal pathways that control cell division and tumor 
      angiogenesis have been developed over the last five years for non small cell lung 
      cancer (NSCLC) with some amazing results, in subgroups of selected patients, 
      predicting more significant success in the upcoming years. Compounds targeted on 
      EGF tyrosine kinase receptor have been tested in large clinical phase 2 and 3 
      trials including thousands of patients. Their efficacy has been proved, in second 
      and third line trials, after first line cisplatin-based chemotherapy for 
      non-mucinous adenocarcinoma in non-smokers, women and Asian patients. Response 
      rates vary from 10% in non selected Caucasian patients to 40% in non-smoking 
      Asian patients with long survivals. Therapeutic targeting improves success rates, 
      either relying on EGFR gene amplification detection by FISH, or search for EGFR 
      tyrosine kinase domain mutations. Commercial kits are available for routine 
      molecular diagnosis of domain mutations potentially enabling molecular targeting 
      in addition to clinical targeting. Angiogenesis inhibitors, especially monoclonal 
      antibody to VEGF, bevacizumab, have also been developed in the last few years. 
      Bevacizumab associated with classical cytotoxic chemotherapy led, in selected 
      patients (with non squamous cell lung cancer and no past history of 
      cardiovascular disease) to an increase of median survival to more than 12 months 
      with tolerable toxicity. Other drugs that have both anti-EGFR activity and 
      anti-angiogenic properties will be soon developed, since future bioactive 
      anti-cancer drugs will probably be multi-targeted drugs.
FAU - Zalcman, G
AU  - Zalcman G
AD  - Service de Pneumologie, UFR de Medecine Caen-Basse Normandie, CHU de Caen, avenue 
      de la Cote-de-Nacre, 14033 Caen Cedex 05. zalcman-g@chu-caen.fr
FAU - Richard, N
AU  - Richard N
FAU - Bergot, E
AU  - Bergot E
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Les nouvelles therapeutiques biologiques du cancer bronchique.
PL  - France
TA  - Rev Pneumol Clin
JT  - Revue de pneumologie clinique
JID - 8406312
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal/administration & dosage/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Bevacizumab
MH  - Biopsy
MH  - Clinical Trials as Topic
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - ErbB Receptors/*antagonists & inhibitors/genetics
MH  - Erlotinib Hydrochloride
MH  - Female
MH  - Forecasting
MH  - Gefitinib
MH  - Humans
MH  - Lung/pathology
MH  - Lung Neoplasms/*drug therapy/genetics/mortality/pathology
MH  - Male
MH  - Mutation
MH  - Patient Selection
MH  - Polymerase Chain Reaction
MH  - Prospective Studies
MH  - Protein Kinase Inhibitors/administration & dosage/*therapeutic use
MH  - Quinazolines/administration & dosage/therapeutic use
MH  - Receptor Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors
RF  - 40
EDAT- 2007/04/26 09:00
MHDA- 2007/06/19 09:00
CRDT- 2007/04/26 09:00
PHST- 2007/04/26 09:00 [pubmed]
PHST- 2007/06/19 09:00 [medline]
PHST- 2007/04/26 09:00 [entrez]
AID - MDOI-RPC-02-2007-63-1-0761-8417-101019-200520001 [pii]
AID - 10.1016/s0761-8417(07)90085-1 [doi]
PST - ppublish
SO  - Rev Pneumol Clin. 2007 Feb;63(1):20-8. doi: 10.1016/s0761-8417(07)90085-1.